Last reviewed · How we verify
VGA039
VGA039 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
VGA039 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | VGA039 |
|---|---|
| Sponsor | Vega Therapeutics, Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, VGA039 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) (PHASE3)
- Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |